ClinicalTrials.Veeva

Menu

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

U

UMC Utrecht

Status

Enrolling

Conditions

Oligometastases
Prostate Neoplasm
Esophageal Cancer
Esophageal Tumor
Tumor
Head and Neck Neoplasms
Liver Cancer
Bladder Cancer
Quality of Life
Liver Neoplasms
Pancreatic Tumor
Rectal Tumor
Rectal Neoplasms
Pancreatic Cancer
Esophagus Cancer
Breast Cancer
Oncology
Radiation Toxicity
Esophagus Tumor
Prostate Tumor
Brain Tumor
Liver Metastases
Lung Cancer
Lung Neoplasm
Breast Tumor
Gynecologic Tumor
Esophagus Neoplasm
Brain Cancer
Bladder Neoplasm
Neoplasms
Lung Tumor
Gynecologic Cancer
Esophageal Neoplasm
Head and Neck Cancer
Prostate Cancer
Head and Neck Tumor
Pancreatic Neoplasms
Rectal Cancer

Treatments

Radiation: Radiation therapy

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04075305
NL66650.041.18

Details and patient eligibility

About

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Full description

Rationale: Radiation therapy has become indispensable in cancer treatment. However, it is associated with severe side effects. Innovation in radiation therapy has resulted in the development of MR-guided radiation therapy (MRGRT) which allows high precision radiotherapy under real time MR visualization. High precision MRGRT has the potential of dose escalation and margin reduction and may potentially lead to higher cure rates and less toxicity. MRGRT can be delivered by the MRI guided Linear Accelerator (MR-Linac) which integrates a state-of-the-art linear accelerator, 1.5T diagnostic quality MRI and an online adaptive workflow.

Objective: The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into clinical practice. In MOMENTUM, technical and clinical data are gathered in order to optimize software, evaluate treatment outcomes, toxicities and progression free, disease free, and overall survival per disease site, and create a repository of anatomical and biological MR sequences to develop new features.

Study design: A multi-institutional, international observational cohort study. Study population: Cancer patients ≥ 18 years receiving treatment and/or imaging on an MR-Linac machine are eligible for enrollment.

Main study parameters/endpoints: MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.

Enrollment

8,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;
  • Patient provides written, informed consent;
  • Patient is 18 years old or older.

Exclusion criteria

  • MRI exclusion criteria, including
  • MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.

Trial design

8,000 participants in 13 patient groups

Brain cancer
Treatment:
Radiation: Radiation therapy
Lung cancer
Treatment:
Radiation: Radiation therapy
Esophageal cancer
Treatment:
Radiation: Radiation therapy
Breast Cancer
Treatment:
Radiation: Radiation therapy
Head and Neck Cancer
Treatment:
Radiation: Radiation therapy
Pancreatic cancer
Treatment:
Radiation: Radiation therapy
Gynecological cancer
Treatment:
Radiation: Radiation therapy
Rectal cancer
Treatment:
Radiation: Radiation therapy
Prostate cancer
Treatment:
Radiation: Radiation therapy
Bladder cancer
Treatment:
Radiation: Radiation therapy
Oligometastases
Treatment:
Radiation: Radiation therapy
Liver cancer
Treatment:
Radiation: Radiation therapy
Other types of cancer
Treatment:
Radiation: Radiation therapy

Trial contacts and locations

18

Loading...

Central trial contact

Tessa Leer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems